The FDA has approved a drug therapy to treat seizures associated with Dravet syndrome–a chronic, rare, and life-threatening form of epilepsy–among patients aged 2 years or older.
This approval comes after the drug was found to be safe and effective in 2 randomized, double-blind, placebo-controlled trials including 655 adults with partial-onset seizures.
Based on evidence from several clinical trials, an FDA advisory committee has voted unanimously to recommend the approval of a cannabis-based oral solution for the treatment of 2 rare forms of epilepsy. ...
Based on evidence from several clinical trials, an FDA advisory committee has voted unanimously to recommend the approval of a cannabis-based oral solution for the treatment of 2 rare forms of epilepsy. ...